Ivosidenib and Enasidenib are FDA approved allosteric inhibitors of mutant-IDH1 and IDH2, respectively, that decrease serum 2-HG levels, induce differentiation of leukaemic blasts and achieve complete remission irrespective of haematological recovery in over 30% of relapsed/refractory and newly diagnosed IDH-mutant AML patients [42,93–98]. Here, IDH1 is linked to acute myeloid leukemia.